EP2231590B9 - Antitumoral compounds - Google Patents

Antitumoral compounds Download PDF

Info

Publication number
EP2231590B9
EP2231590B9 EP08865009A EP08865009A EP2231590B9 EP 2231590 B9 EP2231590 B9 EP 2231590B9 EP 08865009 A EP08865009 A EP 08865009A EP 08865009 A EP08865009 A EP 08865009A EP 2231590 B9 EP2231590 B9 EP 2231590B9
Authority
EP
European Patent Office
Prior art keywords
substituted
unsubstituted
hydrogen
alkenyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP08865009A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2231590B1 (en
EP2231590A1 (en
Inventor
Alberto RODRÍGUEZ VICENTE
María GARRANZO GARCÍA-IBARROLA
Carmen MURCIA PÉREZ
Francisco SÁNCHEZ SANCHO
María del Carmen CUEVAS MARCHANTE
Cristina Mateo Urbano
Isabel Digón Juárez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Priority to SI200830644T priority Critical patent/SI2231590T1/sl
Priority to EP08865009A priority patent/EP2231590B9/en
Priority to PL08865009T priority patent/PL2231590T3/pl
Publication of EP2231590A1 publication Critical patent/EP2231590A1/en
Publication of EP2231590B1 publication Critical patent/EP2231590B1/en
Application granted granted Critical
Publication of EP2231590B9 publication Critical patent/EP2231590B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to new antitumoral compounds, pharmaceutical compositions containing them and their use as antitumoral agents.
  • This compound has been revealed to be a potent antimitotic agent ( Hung DT et al. Chem. Biol. 1996, 3, 287-293 and ter Haar E et al. Biochemistry 1996, 35, 243-250 ), possessing a mode of action similar to that of the clinically proven anticancer agent paclitaxel ( Schiff PB et al. Nature 1979, 277, 665-667 ). Both natural products arrest the cell cycle at the M phase, promote microtubule formation, and have similar inhibitory effects against breast cancer carcinoma (IC 50 of 2.4 nM and 2.1 nM, respectively).
  • Crocacins A-D moderately inhibit the growth of a few Gram-positive bacteria and are potent inhibitors of animal cell cultures and several yeasts and fungi. The most active is crocacin D which showed a MIC of 1.4 ng/mL against the fungus Saccharomyces cerevisiae and strong toxicity (IC 50 of 0.06 mg/L) toward L929 mouse fibroblast cell culture.
  • Cancer is a leading cause of death in animals and humans. Huge efforts have been and are still being undertaken in order to obtain an antitumor agent active and safe to be administered to patients suffering from a cancer.
  • the problem to be solved by the present invention is to provide compounds that are useful in the treatment of cancer.
  • each R a , R b , and R c are independently selected from hydrogen, substituted or unsubstituted C 1 -C 12 alkyl, substituted or unsubstituted C 2 -C 12 alkenyl, substituted or unsubstituted C 2 -C 12 alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclic group.
  • the present invention is also directed to a compound of formula I, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for use as medicament
  • the present invention is also directed to a compound of formula I , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for use as medicament for treating cancer.
  • the present invention is also directed to the use of compounds of formula I , or pharmaceutically acceptable salts, tautomers, or stereoisomers thereof, in the treatment of cancer, or in the preparation of a medicament for the treatment of cancer.
  • the present invention further provides a method of treating any mammal, notably a human, affected by cancer which comprises administering to the affected individual a therapeutically effective amount of a compound of formula I , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
  • the present invention is also directed to a compound of formula I , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for use as anticancer agent.
  • the present invention is directed to pharmaceutical compositions comprising a compound of formula I , or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, together with a pharmaceutically acceptable carrier or diluent.
  • the present invention relates to compounds of general formula I as defined above.
  • Preferred alkenyl and alkynyl groups in the compounds of the present invention may be branched or unbranched, have one or more unsaturated linkages and from 2 to about 12 carbon atoms.
  • One more preferred class of alkenyl and alkynyl groups has from 2 to about 6 carbon atoms. Even more preferred are alkenyl and alkynyl groups having 2, 3 or 4 carbon atoms.
  • Another preferred class of alkenyl and alkynyl groups has from 4 to about 10 carbon atoms, still more preferably 6 to about 10 carbon atoms; and even more preferably 7, 8 or 9 carbon atoms.
  • alkenynyl group as an alkyl group containing one or more double bonds and one or more triple bonds
  • preferred alkenynyl groups are those having from 4 to about 12 carbon atoms.
  • One more preferred class of alkenynyl groups has from 6 to about 10 carbon atoms.
  • Suitable aryl groups in the compounds of the present invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups.
  • Typical aryl groups contain from 1 to 3 separated or fused rings and from 6 to about 18 carbon ring atoms.
  • Preferably aryl groups contain from 6 to about 10 carbon ring atoms.
  • Specially preferred aryl groups include substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted biphenyl, substituted or unsubstituted phenanthryl and substituted or unsubstituted anthryl.
  • Suitable heterocyclic groups include heteroaromatic and heteroalicyclic groups containing from 1 to 3 separated or fused rings and from 5 to about 18 ring atoms.
  • Preferably heteroaromatic and heteroalicyclic groups contain from 5 to about 10 ring atoms, most preferably 5, 6 or 7 ring atoms.
  • Suitable heteroaromatic groups in the compounds of the present invention contain one, two or three heteroatoms selected from N, O or S atoms and include, e.g., coumarinyl including 8-coumarinyl, quinolyl including 8-quinolyl, isoquinolyl, pyridyl, pyrazinyl, pyrazolyl, pyrimidinyl, furyl, pyrrolyl, thienyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, imidazolyl, indolyl, isoindolyl, indazolyl, indolizinyl, phthalazinyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, pyridazinyl, triazinyl, cinnolinyl, benzimi
  • Suitable heteroalicyclic groups in the compounds of the present invention contain one, two or three heteroatoms selected from N, O or S atoms and include, e.g., pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydrothiopyranyl, piperidyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-diox
  • Suitable halogen substituents in the compounds of the present invention include F, Cl, Br and I.
  • Suitable protecting groups for OH are well known for the skilled person in the art.
  • a general review of protecting groups in organic chemistry is provided by Wuts, PGM and Greene TW in Protecting Groups in Organic Synthesis, 4th Ed. Wiley-Interscience , and by Kocienski PJ in Protecting Groups, 3rd Ed. Georg Thieme Verlag .
  • These references provide sections on protecting groups for OH. All these references are incorporated by reference in their entirety. Examples of such protected OH include ethers, silyl ethers, esters, sulfonates, sulfenates and sulfinates, carbonates and carbamates.
  • the protecting group for the OH can be selected from methyl, methoxymethyl, methylthiomethyl, (phenyldimethylsilyl)methoxymethyl, benzyloxymethyl, p -methoxybenzyloxymethyl, [(3,4-dimethoxybenzyl)oxylmethyl, p -nitrobenzyloxymethyl, o-nitrobenzyloxymethyl, [( R )-1-(2-nitrophenyl)ethoxylmethyl, (4-methoxyphenoxy)methyl, guaiacolmethyl, [( p -phenylphenyl)oxy]methyl, t -butoxymethyl, 4-pentenyloxymethyl, siloxymethyl, 2-methoxyethoxymethyl, 2-cyanoethoxymethyl, bis(2-chloroethoxy)methyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, menthoxymethyl, o-bis(2-acetoxyethoxy)methyl
  • the protecting group for the OH can be selected from trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsylil, 2-norbornyldimethylsilyl, t -butyldimethylsilyl, t- butyldiphenylsilyl, tribenzylsilyl, tri-pxylylsilyl, triphenylsilyl, diphenylmethylsilyl, di- t- butylmethylsilyl, bis( t -butyl)-1-pyrenylmethoxysilyl, tris(trimethylsilyl)silyl, (2-hydroxystyryl)dimethylsilyl, (2-hydroxystyryl)diisopropylsilyl, t-butylmethoxyphenylsilyl,
  • the protecting group for the OH can be selected from formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trichloroacetamidate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p -chlorophenoxyacetate, phenylacetate, diphenylacetate, 3-phenylpropionate, bisfluorous chain type propanoyl, 4-pentenoate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, 5[3-bis(4-methoxyphenyl)hydroxymethylphenoxy]levulinate, pivaloate, 1-adamantoate, crotonate, 4-methoxycrotonate, benzoate, p -phenylbenzoate, 2,4,6-trimethylbenzoate, 4-bromobenzoate, 2,5-difluo
  • the protecting group for the OH can be selected from sulfate, allylsulfonate, methanesulfonate, benzylsulfonate, tosylate, 2-[(4-nitrophenyl)ethyl]sulfonate, 2-trifluoromethylbenzenesulfonate, 4-monomethoxytritylsulfenate, alkyl 2,4-dinitrophenylsulfenate, 2,2,5,5-tetramethylpyr-r-ohdin-3-one-l-sulfinate, borate, and dimethylphosphinothiolyl.
  • the protecting group for the OH can be selected from methyl carbonate, methoxymethyl carbonate, 9-fluorenylmethyl carbonate, ethyl carbonate, bromoethyl carbonate, 2-(methylthiomethoxy)ethyl carbonate, 2,2,2-trichloroethyl carbonate, 1,1-dimethyl-2,2,2-trichloroethyl carbonate, 2-(trimethylsilyl) ethyl carbonate, 2-[dimethyl(2-naphthylmethyl)silyl]ethyl carbonate, 2-(phenylsulfonyl) ethyl carbonate, 2-(triphenylphosphonio)ethyl carbonate, cis-[4-[[(methoxytrityl)sulfenyl]oxy]tetrahydrofuran-3-yl]oxy carbonate, isobutyl carbonate, t-butyl carbonate, vinyl carbonate, ally
  • the protecting group for the OH can be selected from dimethylthiocarbamate, N -phenylcarbamate, N- methyl- N -(o-nitrophenyl)carbamate.
  • the mention of these groups should be not interpreted as a limitation of the scope of the invention, since they have been mentioned as a mere illustration of protecting groups for OH, but further groups having said function may be known by the skilled person in the art, and they are to be understood to be also encompassed by the present invention.
  • pharmaceutically acceptable salts, prodrugs refers to any pharmaceutically acceptable salt, ester, solvate, hydrate or any other compound which, upon administration to the patient is capable of providing (directly or indirectly) a compound as described herein.
  • non-pharmaceutically acceptable salts also fall within the scope of the invention since those may be useful in the preparation of pharmaceutically acceptable salts.
  • the preparation of salts can be carried out by methods, known in the art.
  • salts of compounds provided herein are synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods.
  • such salts are, for example, prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent or in a mixture of the two.
  • nonaqueous media like ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.
  • acid addition salts include mineral acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate, and organic acid addition salts such as, for example, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate and p-toluenesulfonate.
  • mineral acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate
  • organic acid addition salts such as, for example, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate and p-toluenesulfonate.
  • alkali addition salts include inorganic salts such as, for example, sodium, potassium, calcium and ammonium salts, and organic alkali salts such as, for example, ethylenediamine, ethanolamine, N,N-dialkylenethanolamine, triethanolamine and basic aminoacids salts.
  • the compounds of the invention may be in crystalline form either as free compounds or as solvates (e.g. hydrates) and it is intended that both forms are within the scope of the present invention.
  • Methods of solvation are generally known within the art.
  • prodrug any compound that is a prodrug of a compound of formula I is not within the scope and spirit of the invention.
  • prodrug as used in this application is defined here as meaning a chemical compound having undergone a chemical derivation such as substitution or addition of a further chemical group to change (for pharmaceutical use) any of its physico-chemical properties, such as solubility or bioavailability, e.g. ester and ether derivatives of an active compound that yield the active compound per se after administration to a subject. Examples of well known methods of producing a prodrug of a given acting compound are known to those skilled in the art and can be found e.g. in Krogsgaard-Larsen et al., Textbook of Drugdesign and Discovery, Taylor & Francis (April 2002 ).
  • any compound referred to herein is intended to represent such specific compound as well as certain variations or forms.
  • compounds referred to herein may have asymmetric centres and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds referred to herein, and mixtures thereof, are considered within the scope of the present invention.
  • any given compound referred to herein is intended to represent any one of a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof.
  • the compounds of the present invention represented by the above described formula I may include enantiomers depending on their asymmetry or diastereoisomers.
  • Stereoisomerism about the double bond is also possible, therefore in some cases the molecule could exist as (E)-isomer or (Z)-isomer. If the molecule contains several double bonds, each double bond will have its own stereoisomerism, that could be the same or different than the stereoisomerism of the other double bonds of the molecule.
  • the single isomers and mixtures of isomers fall within the scope of the present invention.
  • compounds referred to herein may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers.
  • tautomer refers to one of two or more structural isomers of a compound, that exist in equilibrium and are readily converted from one isomeric form to another. Common tautomeric pairs are amine-imine, amide-imide, keto-enol, lactam-lactim, etc.
  • any compound referred to herein is intended to represent hydrates, solvates, and polymorphs, and mixtures thereof when such forms exist in the medium.
  • compounds referred to herein may exist in isotopically-labelled forms. All geometric isomers, tautomers, atropisomers, hydrates, solvates, polymorphs, and isotopically labelled forms of the compounds referred to herein, and mixtures thereof, are considered within the scope of the present invention.
  • R ay , R by , and R cy are hydrogen and substituted or unsubstituted C 1 -C 12 alkyl. More preferred Ray, R by , and R cy are hydrogen and substituted or unsubstituted C 1 -C 6 alkyl, and even more preferred is hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted isopropyl, and substituted or unsubstituted butyl, including substituted or unsubstituted tert-butyl, substituted or unsubstituted isobutyl, and substituted or unsubstituted sec-butyl.
  • substituents may be chosen from the foregoing list.
  • Hydrogen and methyl are the most preferred R ay , R by , and R cy groups.
  • R 1 , R 2 , R 3 , R 4 , and R 5 are hydrogen and substituted or unsubstituted C 1 -C 12 alkyl. More preferred R 1 , R 2 , R 3 , R 4 , and R 5 are hydrogen and substituted or unsubstituted C 1 -C 6 alkyl, and even more preferred is hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted isopropyl and substituted or unsubstituted butyl, including substituted or unsubstituted tert-butyl, substituted or unsubstituted isobutyl and substituted or unsubstituted sec-butyl.
  • substituents may be chosen from the foregoing list.
  • Hydrogen, methyl, isopropyl, tert-butyl, and benzyl are the most preferred R 1 , R 2 , R 3 , R 4 , and R 5 groups.
  • particularly preferred R 1 , R 2 , R 3 , and R 4 are hydrogen.
  • particularly preferred R 5 are methyl, isopropyl, and tert-butyl.
  • W is NR 7 wherein R 7 is as defined before.
  • Particularly preferred R 7 is hydrogen and substituted or unsubstituted C 1 -C 12 alkyl. More preferred R 7 is hydrogen and substituted or unsubstituted C 1 -C 6 alkyl; and even more preferred is hydrogen, methyl, ethyl, propyl, isopropyl and butyl, including tert-butyl. Hydrogen is the most preferred.
  • R 7 and R 5 together with the corresponding N atom and C atom to which they are attached form a substituted or unsubstituted heterocyclic group.
  • preferred heterocyclic group is a heteroalicyclic group containing one, two or three heteroatoms selected from N, O or S atoms, most preferably one N atom, and having from 5 to about 10 ring atoms, most preferably 5, 6 or 7 ring atoms.
  • a pyrrolidine group is the most preferred.
  • R 6 is NR 8 R 9 and OR 10 wherein R 8 , R 9 , and R 10 are as defined before, and even more preferred R 6 is NR 8 R 9 .
  • Particularly preferred R 8 is hydrogen.
  • R 9 is hydrogen, substituted or unsubstituted C 2 -C 12 alkenyl, substituted or unsubstituted C 2 -C 12 alkynyl, and substituted or unsubstituted C 4 -C 12 alkenynyl.
  • the preferred substituted alkenyl, substituted alkynyl and substituted alkenynyl may present not only one but two or more substituents. More preferred alkenyl groups are those having from 6 to about 10 carbon atoms; and even more preferably 7, 8 or 9 carbon atoms.
  • Octa-1,6-dienyl, octa-1,5-dienyl, octa-1,4-dienyl, octa-1,3-dienyl, nona-1,7-dienyl, nona-1,6-dienyl, nona-1,5-dienyl, nona-1,4-dienyl, nona-1,3-dienyl, hepta-1, 5-dienyl, hepta-1, 4-dienyl, hepta-1, 3-dienyl are the most preferred alkenyl groups.
  • more preferred alkynyl groups are those having from 6 to about 10 carbon atoms; and even more preferably 7, 8 or 9 carbon atoms.
  • Oct-7-ynyl, oct-6-ynyl, oct-5-ynyl, oct-4-ynyl, oct-3-ynyl, oct-2-ynyl, oct-1-ynyl, non-8-ynyl, non-7-ynyl, non-6-ynyl, non-5-ynyl, non-4-ynyl, non-3-ynyl, non-2-ynyl, non-1-ynyl, hept-6-ynyl, hept-5-ynyl, hept-4-ynyl, hept-3-ynyl, hept-2-ynyl, and hept-1-ynyl are the most preferred alkynyl groups.
  • more preferred alkenynyl groups are those having from 6 to about 10 carbon atoms; and even more preferably 7, 8 or 9 carbon atoms.
  • the protecting group for the OH is preferably selected from trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsylil, 2-norbornyldimethylsilyl, t- butyldimethylsilyl, t-butyldiphenylsilyl, tribenzylsilyl, tri- p -xylylsilyl, triphenylsilyl, diphenylmethylsilyl, di- t -butylmethylsilyl, bis(t-butyl)-l-pyrenylmethoxysilyl, tris(trimethylsilyl)silyl, (2-hydroxystyryl)dimethylsilyl, (2-hydroxystyryl)diisoprop
  • Particularly preferred R 11 , R 12 , R 13 , R 14 , and R 15 are hydrogen, OR a , OCOR a , and OSiR a R b R c , wherein R a , R b , and R c are as defined above.
  • Particular preferred R 11 , R 14 , and R 15 are hydrogen, particular preferred R 12 is hydrogen and OR a
  • particular preferred R 13 is hydrogen, OR a , and OSiR a R b R c .
  • Particular preferred R a , R b , and R c are hydrogen and substituted or unsubstituted C 1 -C 12 alkyl.
  • R a , R b , and R c are hydrogen and substituted or unsubstituted C 1 -C 6 alkyl; and even more preferred are hydrogen, methyl, ethyl, propyl, isopropyl and butyl, including tert-butyl, being hydrogen, methyl, and tert-butyl the most preferred.
  • each double bond may exist as (E) or (Z).
  • the single isomers and mixtures of the isomers fall within the scope of the present invention.
  • preferred compounds of general formula I are those also having general formula IA or pharmaceutically acceptable salts, tautomers, or stereoisomers thereof
  • R ay , R by , and R cy are hydrogen and substituted or unsubstituted C 1 -C 12 alkyl. More preferred R ay , R by , and R cy are hydrogen and substituted or unsubstituted C 1 -C 6 alkyl, and even more preferred is hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted isopropyl, and substituted or unsubstituted butyl, including substituted or unsubstituted tert-butyl, substituted or unsubstituted isobutyl, and substituted or unsubstituted sec-butyl.
  • substituents may be chosen from the foregoing list.
  • Hydrogen and methyl are the most preferred Ray, R by , and R cy groups.
  • R ay is methyl
  • particularly preferred Ray is hydrogen or methyl
  • particular preferred R by is hydrogen
  • particularly preferred R cy is methyl
  • R 5 is hydrogen and substituted or unsubstituted C 1 -C 12 alkyl. More preferred R 5 is hydrogen and substituted or unsubstituted C 1 -C 6 alkyl, and even more preferred is hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted isopropyl and substituted or unsubstituted butyl, including substituted or unsubstituted tert-butyl, substituted or unsubstituted isobutyl and substituted or unsubstituted sec-butyl.
  • substituents may be chosen from the foregoing list.
  • Hydrogen, methyl, isopropyl, tert-butyl, and benzyl are the most preferred R 5 groups, and even most preferred methyl, isopropyl, and tert-butyl.
  • W is NR 7 wherein R 7 is as defined before.
  • Particularly preferred R 7 is hydrogen and substituted or unsubstituted C 1 -C 12 alkyl. More preferred R 7 is hydrogen and substituted or unsubstituted C 1 -C 6 alkyl; and even more preferred is hydrogen, methyl, ethyl, propyl, isopropyl and butyl, including tert-butyl. Hydrogen is the most preferred.
  • R 7 and R 5 together with the corresponding N atom and C atom to which they are attached form a substituted or unsubstituted heterocyclic group.
  • preferred heterocyclic group is a heteroalicyclic group containing one, two or three heteroatoms selected from N, O or S atoms, most preferably one N atom, and having from 5 to about 10 ring atoms, most preferably 5, 6 or 7 ring atoms.
  • a pyrrolidine group is the most preferred.
  • R 6 is NR 8 R 9 and OR 10 wherein R 8 , R 9 , and R 10 are as defined before, and even more preferred R 6 is NR 8 R 9 .
  • Particularly preferred R 8 is hydrogen.
  • R 9 is hydrogen, substituted or unsubstituted C 2 -C 12 alkenyl, substituted or unsubstituted C 2 -C 12 alkynyl, and substituted or unsubstituted C 4 -C 12 alkenynyl.
  • the preferred substituted alkenyl, substituted alkynyl, and substituted alkenynyl may present not only one but two or more substituents. More preferred alkenyl groups are those having from 6 to about 10 carbon atoms; and even more preferably 7, 8 or 9 carbon atoms.
  • more preferred alkynyl groups are those having from 6 to about 10 carbon atoms; and even more preferably 7, 8 or 9 carbon atoms.
  • Oct-7-ynyl, oct-6-ynyl, oct-5-ynyl, oct-4-ynyl, oct-3-ynyl, oct-2-ynyl, oct-1-ynyl, non-8-ynyl, non-7-ynyl, non-6-ynyl, non-5-ynyl, non-4-ynyl, non-3-ynyl, non-2-ynyl, non-1-ynyl, hept-6-ynyl, hept-5-ynyl, hept-4-ynyl, hept-3-ynyl, hept-2-ynyl, and hept-1-ynyl are the most preferred alkynyl groups.
  • more preferred alkenynyl groups are those having from 6 to about 10 carbon atoms; and even more preferably 7, 8 or 9 carbon atoms.
  • the protecting group for the OH is preferably selected from trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsylil, 2-norbornyldimethylsilyl, t- butyldimethylsilyl, t -butyldiphenylsilyl, tribenzylsilyl, tri- p -xylylsilyl, triphenylsilyl, diphenylmethylsilyl, di- t -butylmethylsilyl, bis( t -butyl)-1-pyrenylmethoxysilyl, tris(trimethylsilyl)silyl, (2-hydroxystyryl)dimethylsilyl, (2-hydroxystyryl)diis
  • R 12 and R 13 are hydrogen, OR a , OCOR a , and OSiR a R b R c , wherein R a , R b , and R c are as defined above. Even more preferred R 12 is hydrogen and OR a , and more preferred R 13 is hydrogen, OR a , and OSiR a R b R c . Particular preferred R a , R b , and R c are hydrogen and substituted or unsubstituted C 1 -C 12 alkyl.
  • R a , R b , and R c are hydrogen and substituted or unsubstituted C 1 -C 6 alkyl; and even more preferred are hydrogen, methyl, ethyl, propyl, isopropyl and butyl, including tert-butyl, being hydrogen, methyl, and tert-butyl the most preferred.
  • each double bond may exist as (E) or (Z).
  • the single isomers and mixtures of the isomers fall within the scope of the present invention.
  • the compounds of the invention can be obtained synthetically by joining different fragments as indicated in the Scheme A.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , R 14 , R 15 , Y and W are the desired groups or an appropriate protecting group as needed, and J, K, L, and M are appropriate reacting or leaving groups.
  • the compounds of the invention can be obtained by either of the following strategies:
  • Fragments A, B, C and D can be independently prepared following standard procedures in organic synthesis.
  • Deprotection of the protecting groups can be achieved according to known procedures in organic synthesis ( Greene and Wuts, Protective Groups in Organic Synthesis, 3rd ed., Wiley-Interscience ; Burke and Danheiser, Handbook of Reagents for Organic Synthesis: Oxidizing and Reducing Agents, Wiley ; Pla D et al. J. Org. Chem. 2005, 70, 8231 ).
  • Suitable protecting groups can be used on the substituents to ensure that reactive groups are not affected.
  • the synthesis can be designed to employ precursor substituents which can be converted at the appropriate stage to a desired substituent. Saturation or unsaturation in the ring-structure can be introduced or removed as part of the synthesis. Starting materials and reagents can be modified as desired to ensure synthesis of the intended compound.
  • analogues can also be synthesized from the obtained compounds by usual procedures in synthetic organic chemistry which are known by a person skilled in the art.
  • the synthetic routes above mentioned can be modified as desired to give stereospecific compounds as well as mixtures of stereoisomers. It is possible to synthesize specific stereoisomers or specific mixtures by various methods including the use of stereospecific reagents or by introducing chiral centers into the compounds during the synthesis. It is possible to introduce one or more stereocenters during synthesis and also invert existing stereocenters. In addition, it is possible to separate stereoisomers once the compound has been synthesized by standard resolution techniques known to the skilled reader.
  • compositions of compounds of general formula I that possess cytotoxic activity and their use as antitumor agents.
  • present invention further provides pharmaceutical compositions comprising a compound of this invention, a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof with a pharmaceutically acceptable carrier.
  • carrier refers to a diluent, adjuvant, excipient or vehicle with which the active ingredient is administered. Suitable pharmaceutical carriers are described in " Remington's Pharmaceutical Sciences” by E. W. Martin, 1995 .
  • compositions include any solid (tablets, pills, capsules, granules, etc.) or liquid (solutions, suspensions or emulsions) compositions for oral, topical or parenteral administration.
  • Administration of the compounds or compositions of the present invention may be by any suitable method, such as intravenous infusion, oral preparations, and intraperitoneal and intravenous administration.
  • infusion times of up to 24 hours are used, more preferably 1-12 hours, with 1-6 hours most preferred. Short infusion times which allow treatment to be carried out without an overnight stay in hospital are especially desirable. However, infusion may be 12 to 24 hours or even longer if required. Infusion may be carried out at suitable intervals of say 1 to 4 weeks.
  • Pharmaceutical compositions containing compounds of the invention may be delivered by liposome or nanosphere encapsulation, in sustained release formulations or by other standard delivery means.
  • the correct dosage of the compounds will vary according to the particular formulation, the mode of application, and the particular situs, host and tumour being treated. Other factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account. Administration can be carried out continuously or periodically within the maximum tolerated dose.
  • the compounds and compositions of this invention may be used with other drugs to provide a combination therapy.
  • the other drugs may form part of the same composition, or be provided as a separate composition for administration at the same time or at different time.
  • Antitumoral activities of these compounds include, but are not limited, lung cancer, colon cancer, and breast cancer.
  • Scheme 1 provides an example of the synthesis of fragments 12 and 13.
  • a resealable Schlenk tube was charged with copper (I) iodide (148 mg, 0.78 mmol), potassium carbonate (1.076 g, 7.78 mmol) and Boc -tert- LeuCONH 2 (prepared following the procedure described in Pozdnev, V. F., Tetrahedron Letters 1995, 36, 7115-7118 ) (0.96 g, 4.15 mmol), evacuated and filled with N 2 .
  • N , N -Dimethylethylenediamine (DMEDA) (0.166 mL, 1.55 mmol
  • vinyl iodide 9 (1.04g, 2.59 mmol
  • anhydrous DMF 15 mL
  • a resealable Schlenk tube was charged with copper (I) iodide (40.4 mg, 0.213 mmol), potassium carbonate (294 mg, 2.13 mmol) and Boc- Val- CONH 2 (prepared following the procedure described in Pozdnev, V. F., Tetrahedron Letters 1995, 36, 7115-7118 ) (230 mg, 1.06 mmol), evacuated and filled with N 2 .
  • N , N' -Dimethylethylenediamine (45 ⁇ L, 0.426 mmol), vinyl iodide 9 (283 mg, 0.71 mmol) and anhydrous DMF (35 mL) were added under N 2 .
  • DIPEA Diisopropylethylamine
  • HOAt 1-Hydroxy-7-azabenzotriazole
  • HATU N,N,N',N'-Tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate
  • Scheme 2 provides an example of the synthesis of fragment 18.
  • Scheme 3 provides an example of the synthesis of fragment 22.
  • Scheme 4 provides an example of the synthesis of fragment 26.
  • Scheme 5 provides an example of the synthesis of fragment 29.
  • EXAMPLE 10 BIOASSAYS FOR THE DETECTION OF ANTITUMOR ACTIVITY
  • the aim of this assay is to evaluate the in vitro cytostatic (ability to delay or arrest tumor cell growth) or cytotoxic (ability to kill tumor cells) activity of the samples being tested.
  • N° ATCC Species Tissue Characteristics A549 CCL-185 human lung lung carcinoma (NSCLC) HT29 HTB-38 human colon colorectal adenocarcinoma MDA-MB-231 HTB-26 human breast breast adenocarcinoma
  • SRB sulforhodamine B
  • This form of assay employs SBS-standard 96-well cell culture microplates ( Faircloth et al. Methods in Cell Science, 1988, 11(4), 201-205 ; Mosmann et al, Journal of Immunological. Methods, 1983, 65(1-2), 55-63 ). All the cell lines used in this study, derived from different types of human cancer, were obtained from the American Type Culture Collection (ATCC).
  • ATCC American Type Culture Collection
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS Fetal Bovine Serum
  • 2mM L-glutamine 100 U/mL penicillin and 100 U/mL streptomycin at 37°C, 5% CO 2 and 98% humidity.
  • cells were harvested from subconfluent cultures using trypsinization and resuspended in fresh medium before counting and plating.
  • the antitumor effect was estimated by the SRB method: Briefly, cells were washed twice with PBS, fixed for 15 min in 1% glutaraldehyde solution, rinsed twice in PBS, and stained in 0.4% SRB solution for 30 min at room temperature. Cells were then rinsed several times with 1% acetic acid solution and air-dried. SRB was then extracted in 10mM trizma base solution and the absorbance measured in an automated spectrophotometric plate reader at 490 nm. Cell survival was expressed as percentage of control cell growth. The final effect of the sample being tested was estimated by applying the NCI algorithm ( Boyd MR and Paull KD. Drug Dev. Res. 1995, 34, 91-104 ).
  • GI 50 concentration that produces 50% growth inhibition
  • TGI total growth inhibition (cytostatic effect)
  • LC 50 concentration that produces 50% net cell killing (cytotoxic effect).
  • Table 1 illustrates data on the biological activity of compounds of the present invention.
  • Table 1 Cytotoxicity assay - Activity Data (Molar) Compound 30 Compound 32 Compound 33 Compound 34 MDA-MB-231 GI 50 7.64E-07 8.33E-07 3.01E-06 1.03E-06 TGI 9.74E-07 1.11E-06 4.81E-06 4.43E-06 LC 50 1.26E-06 1.50E-06 8.01E-06 > 1.84E-05 A549 GI 50 6.71E-07 4.90E-07 1.58E-06 7.01E-07 TGI 7.64E-07 6.86E-07 3.41E-06 2.77E-06 LC 50 9.08E-07 1.06E-06 7.41E-06 > 1.84E-05 HT29 GI 50 7.77E-07 4.90E-07 1.10E-06 4.43E-07 TGI 8.16E-07 6.21E-07 1.82E-06 5.72E-07 LC 50 8.69E-07 8.49E-07 3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compounds Of Unknown Constitution (AREA)
EP08865009A 2007-12-20 2008-12-19 Antitumoral compounds Active EP2231590B9 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI200830644T SI2231590T1 (sl) 2007-12-20 2008-12-19 Antitumorne spojine
EP08865009A EP2231590B9 (en) 2007-12-20 2008-12-19 Antitumoral compounds
PL08865009T PL2231590T3 (pl) 2007-12-20 2008-12-19 Związki przeciwnowotworowe

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07123882 2007-12-20
EP08865009A EP2231590B9 (en) 2007-12-20 2008-12-19 Antitumoral compounds
PCT/EP2008/068065 WO2009080769A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Publications (3)

Publication Number Publication Date
EP2231590A1 EP2231590A1 (en) 2010-09-29
EP2231590B1 EP2231590B1 (en) 2012-03-14
EP2231590B9 true EP2231590B9 (en) 2012-08-15

Family

ID=40580474

Family Applications (3)

Application Number Title Priority Date Filing Date
EP08865009A Active EP2231590B9 (en) 2007-12-20 2008-12-19 Antitumoral compounds
EP08864895.1A Active EP2231633B1 (en) 2007-12-20 2008-12-19 Antitumoral compounds
EP13154647.5A Active EP2597091B1 (en) 2007-12-20 2008-12-19 Antitumoral Compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP08864895.1A Active EP2231633B1 (en) 2007-12-20 2008-12-19 Antitumoral compounds
EP13154647.5A Active EP2597091B1 (en) 2007-12-20 2008-12-19 Antitumoral Compounds

Country Status (27)

Country Link
US (4) US9187445B2 (zh)
EP (3) EP2231590B9 (zh)
JP (3) JP5727228B2 (zh)
KR (3) KR101541436B1 (zh)
CN (4) CN101903367B (zh)
AT (1) ATE549313T1 (zh)
AU (2) AU2008341671B2 (zh)
BR (2) BRPI0821116B8 (zh)
CA (2) CA2715203C (zh)
CY (1) CY1117245T1 (zh)
DK (2) DK2231633T3 (zh)
ES (3) ES2442140T3 (zh)
HK (3) HK1147998A1 (zh)
HR (2) HRP20120464T1 (zh)
IL (3) IL206397A (zh)
MX (2) MX2010006796A (zh)
MY (3) MY164533A (zh)
NZ (3) NZ597526A (zh)
PL (2) PL2231590T3 (zh)
PT (2) PT2231590E (zh)
RS (2) RS52343B (zh)
RU (3) RU2493147C2 (zh)
SG (2) SG170779A1 (zh)
SI (2) SI2231633T1 (zh)
UA (3) UA106967C2 (zh)
WO (2) WO2009080769A1 (zh)
ZA (3) ZA201004018B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52343B (en) 2007-12-20 2012-12-31 Pharma Mar S.A. ANTITUMOR UNITS
CN104039315B (zh) * 2012-01-05 2016-08-24 花王株式会社 用于降低感觉刺激的制剂
TWI631119B (zh) 2013-04-16 2018-08-01 愛杜西亞製藥有限公司 抗菌雙芳香族衍生物
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4855086A (en) * 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
JPS61109717A (ja) * 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
JPH0539283A (ja) * 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en) * 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US6380400B1 (en) 1998-09-11 2002-04-30 Victor Fedij Methods of making dihydropyrone HIV protease inhibitors
NZ510013A (en) 1998-09-11 2003-11-28 Warner Lambert Co Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors
AU2000241948A1 (en) * 2000-04-04 2001-10-15 Novartis Ag Method for treating cells resistant to antineoplastic agents
ES2532607T3 (es) * 2002-03-04 2015-03-30 Merck Hdac Research, Llc Métodos de inducción de la diferenciación terminal
JP2006528611A (ja) * 2003-07-25 2006-12-21 ノバルティス アクチエンゲゼルシャフト 置換ラクタムおよびそれらの抗がん剤としての使用
RU2006142690A (ru) * 2004-06-03 2008-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Соединения лептомицина
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
WO2007014423A1 (en) * 2005-08-02 2007-02-08 Medvet Science Pty, Ltd. Exercise apparatus
CN102336730A (zh) 2006-06-16 2012-02-01 马尔药品公司 抗肿瘤二羟基吡喃-2-酮化合物
RS52343B (en) 2007-12-20 2012-12-31 Pharma Mar S.A. ANTITUMOR UNITS

Also Published As

Publication number Publication date
IL206396A (en) 2014-05-28
CN101903367A (zh) 2010-12-01
MX2010006795A (es) 2010-10-26
US9827257B2 (en) 2017-11-28
PT2231590E (pt) 2012-06-25
KR20100100979A (ko) 2010-09-15
NZ597526A (en) 2012-06-29
HK1147990A1 (en) 2011-08-26
CN101903367B (zh) 2015-08-05
EP2231590B1 (en) 2012-03-14
ZA201106371B (en) 2013-05-29
IL206396A0 (en) 2010-12-30
RU2528393C9 (ru) 2015-01-10
JP5860088B2 (ja) 2016-02-16
RS53140B (en) 2014-06-30
RU2528393C1 (ru) 2014-09-20
EP2597091A1 (en) 2013-05-29
IL229594A0 (en) 2014-01-30
MX2010006796A (es) 2010-10-26
CN101903337A (zh) 2010-12-01
ES2384420T3 (es) 2012-07-04
RU2010130253A (ru) 2012-01-27
ES2578606T3 (es) 2016-07-28
SG170778A1 (en) 2011-05-30
CY1117245T1 (el) 2017-04-05
SI2231590T1 (sl) 2012-10-30
EP2231633A1 (en) 2010-09-29
KR101579553B1 (ko) 2015-12-22
RU2489429C2 (ru) 2013-08-10
KR20150076265A (ko) 2015-07-06
US20110034549A1 (en) 2011-02-10
BRPI0821114B8 (pt) 2021-11-09
EP2231590A1 (en) 2010-09-29
EP2231633B1 (en) 2013-10-30
CN101903337B (zh) 2013-12-18
CA2710087A1 (en) 2009-07-02
JP5529038B2 (ja) 2014-06-25
SI2231633T1 (sl) 2014-02-28
IL229594A (en) 2016-02-29
HK1147998A1 (en) 2011-08-26
RU2013112003A (ru) 2014-08-20
AU2008341670B2 (en) 2012-04-19
AU2008341671A1 (en) 2009-07-02
BRPI0821116A2 (pt) 2015-08-11
HRP20120464T1 (hr) 2012-07-31
US9750759B2 (en) 2017-09-05
HRP20140015T1 (hr) 2014-02-14
ZA201004017B (en) 2011-12-28
PL2231633T3 (pl) 2014-03-31
NZ586012A (en) 2011-11-25
US20100280108A1 (en) 2010-11-04
AU2008341670A1 (en) 2009-07-02
CA2710087C (en) 2015-06-02
US20120041063A2 (en) 2012-02-16
RU2493147C2 (ru) 2013-09-20
CN102174058A (zh) 2011-09-07
JP2011506578A (ja) 2011-03-03
BRPI0821114A2 (pt) 2015-06-16
ZA201004018B (en) 2011-12-28
MY148651A (en) 2013-05-15
DK2231633T3 (da) 2014-01-20
UA119963C2 (uk) 2019-09-10
PL2231590T3 (pl) 2012-09-28
ATE549313T1 (de) 2012-03-15
BRPI0821116B1 (pt) 2020-02-18
PT2231633E (pt) 2014-01-20
WO2009080769A1 (en) 2009-07-02
BRPI0821116B8 (pt) 2021-05-25
US9187445B2 (en) 2015-11-17
US20150342972A1 (en) 2015-12-03
UA106967C2 (uk) 2014-11-10
WO2009080761A1 (en) 2009-07-02
IL206397A (en) 2014-01-30
CA2715203A1 (en) 2009-07-02
IL206397A0 (en) 2010-12-30
CN102190643B (zh) 2015-02-25
HK1180678A1 (zh) 2013-10-25
BRPI0821114B1 (pt) 2021-09-08
UA104281C2 (ru) 2014-01-27
KR101541436B1 (ko) 2015-08-03
KR101639772B1 (ko) 2016-07-15
DK2231590T3 (da) 2012-07-09
JP5727228B2 (ja) 2015-06-03
US8710264B2 (en) 2014-04-29
SG170779A1 (en) 2011-05-30
MY155342A (en) 2015-10-15
EP2597091B1 (en) 2016-04-20
NZ586013A (en) 2012-02-24
KR20100125226A (ko) 2010-11-30
JP2011506575A (ja) 2011-03-03
CN102190643A (zh) 2011-09-21
RS52343B (en) 2012-12-31
MY164533A (en) 2017-12-29
US20150344454A1 (en) 2015-12-03
RU2010130180A (ru) 2012-01-27
CA2715203C (en) 2015-09-08
AU2008341671B2 (en) 2012-07-26
JP2014133752A (ja) 2014-07-24
ES2442140T3 (es) 2014-02-25

Similar Documents

Publication Publication Date Title
US8501968B2 (en) Antitumoral dihydropyran-2-one compounds
US9827257B2 (en) Antitumoral compounds
ANTITUIMIORAL The present invention relates to new antitumoral compounds, pharmaceutical compositions containing them and their use as antitumoral agents.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100715

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20110216

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1147990

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 549313

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008014193

Country of ref document: DE

Effective date: 20120510

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20120464

Country of ref document: HR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20120614

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2384420

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120704

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20120314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120314

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20120464

Country of ref document: HR

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 11869

Country of ref document: SK

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20120314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120314

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20120401331

Country of ref document: GR

Effective date: 20120713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120314

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120314

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120314

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120714

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1147990

Country of ref document: HK

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E014497

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20121217

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008014193

Country of ref document: DE

Effective date: 20121217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121219

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151219

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20170710

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20120464

Country of ref document: HR

Payment date: 20181207

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20120464

Country of ref document: HR

Payment date: 20191204

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20120464

Country of ref document: HR

Payment date: 20201204

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20120464

Country of ref document: HR

Payment date: 20211203

Year of fee payment: 14

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20120464

Country of ref document: HR

Payment date: 20221207

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20221205

Year of fee payment: 15

Ref country code: SE

Payment date: 20221227

Year of fee payment: 15

Ref country code: PT

Payment date: 20221209

Year of fee payment: 15

Ref country code: NO

Payment date: 20221228

Year of fee payment: 15

Ref country code: NL

Payment date: 20221226

Year of fee payment: 15

Ref country code: IE

Payment date: 20221227

Year of fee payment: 15

Ref country code: GB

Payment date: 20221227

Year of fee payment: 15

Ref country code: FR

Payment date: 20221227

Year of fee payment: 15

Ref country code: FI

Payment date: 20221227

Year of fee payment: 15

Ref country code: DK

Payment date: 20221227

Year of fee payment: 15

Ref country code: CZ

Payment date: 20221207

Year of fee payment: 15

Ref country code: BG

Payment date: 20221212

Year of fee payment: 15

Ref country code: AT

Payment date: 20221202

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20221202

Year of fee payment: 15

Ref country code: PL

Payment date: 20221202

Year of fee payment: 15

Ref country code: HU

Payment date: 20221207

Year of fee payment: 15

Ref country code: HR

Payment date: 20221207

Year of fee payment: 15

Ref country code: GR

Payment date: 20221229

Year of fee payment: 15

Ref country code: BE

Payment date: 20221227

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20221219

Year of fee payment: 15

Ref country code: ES

Payment date: 20230102

Year of fee payment: 15

Ref country code: CH

Payment date: 20230109

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20221228

Year of fee payment: 15

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230519

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231220

Year of fee payment: 16

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20120464

Country of ref document: HR

Effective date: 20231219

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008014193

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20231231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231219

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231219

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231219

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231219

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240619

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20240101

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 11869

Country of ref document: SK

Effective date: 20231219

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 549313

Country of ref document: AT

Kind code of ref document: T

Effective date: 20231219

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20231219

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20231231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240619

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240101

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20240816

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231219

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231219

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240702

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240712

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231